Multiple Myeloma

Featured

News
Daratumumab, lenalidomide, and dexamethasone (DRd) yielded faster and sustained clinically meaningful improvements in PROs compared with lenalidomide and dexamethasone (Rd) for…
Special Reports
While there is no cure for MM, a number of treatments are in the research and development pipeline. Clinicians are…
Conference Coverage
Findings from a single center study show that the outpatient setting is safe, effective, and reduces the total length…
Conference Coverage
A recent study assessed the comparative efficacy and cost-effectiveness of daratumumab plus pomalidomide and…
Videos
Robert Rifkin, MD, discusses results from the TOURMALINE-MM2 trial which compared ixazomib, lenalidomide, and…